PriceTargets.com logo

Motus GI - MOTS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.88
  • Forecasted Upside: 37,993.67%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.08 As of 04/19/2024 01:00 AM ET
▲ +0.01 (15.20%)

This chart shows the closing price for MOTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Motus GI Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MOTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MOTS

Analyst Price Target is $28.88
▲ +37,993.67% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Motus GI in the last 3 months. The average price target is $28.88, with a high forecast of $37.50 and a low forecast of $20.25. The average price target represents a 37,993.67% upside from the last price of $0.08.

This chart shows the closing price for MOTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Motus GI. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$37.50Low
8/17/2023Alliance Global PartnersLower Target$24.75 ➝ $20.25Low
8/16/2023HC WainwrightReiterated RatingBuy ➝ Buy$37.50Low
6/15/2023HC WainwrightLower Target$150.00 ➝ $37.50Low
1/25/2023LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
11/17/2022OppenheimerLower Target$75.00Low
11/15/2022Alliance Global PartnersLower Target$180.00 ➝ $33.75Low
11/15/2022HC WainwrightLower TargetBuy$165.00 ➝ $150.00Low
11/14/2022Piper SandlerLower TargetOverweight$150.00 ➝ $90.00Low
8/15/2022HC WainwrightLower TargetBuy$300.00 ➝ $165.00Low
8/11/2022Alliance Global PartnersLower Target$360.00 ➝ $180.00Low
5/16/2022HC WainwrightLower TargetNA$600.00 ➝ $450.00High
3/22/2022Colliers SecuritiesReiterated RatingBuyLow
1/26/2022Alliance Global PartnersLower Target$525.00 ➝ $420.00High
11/15/2021HC WainwrightReiterated RatingBuy$600.00Medium
9/9/2021HC WainwrightReiterated RatingBuy$600.00Low
8/12/2021Piper SandlerLower TargetPositive ➝ Overweight$750.00 ➝ $450.00High
6/4/2021HC WainwrightReiterated RatingBuy$600.00High
5/14/2021Alliance Global PartnersLower TargetBuy$750.00 ➝ $615.00Medium
11/16/2020HC WainwrightLower TargetBuy$900.00 ➝ $600.00High
11/12/2020Piper SandlerLower TargetOverweight$900.00 ➝ $750.00High
9/9/2020Alliance Global PartnersBoost TargetBuy$495.00 ➝ $780.00Medium
8/12/2020Colliers SecuritiesReiterated RatingBuyLow
8/12/2020OppenheimerReiterated RatingBuy$750.00High
6/16/2020HC WainwrightReiterated RatingBuy$900.00High
5/14/2020OppenheimerInitiated CoverageBuy$900.00High
4/21/2020HC WainwrightInitiated CoverageBuy$900.00Medium
3/31/2020Piper SandlerLower Target$1,200.00 ➝ $900.00Low
9/26/2019Dougherty & CoSet TargetBuy$2,100.00High
5/10/2019Piper Sandler CompaniesLower Target$2,400.00 ➝ $1,800.00Low
(Data available from 4/20/2019 forward)

News Sentiment Rating

-0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Motus GI logo
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.
Read More

Today's Range

Now: $0.08
Low: $0.07
High: $0.08

50 Day Range

MA: $0.53
Low: $0.07
High: $1.10

52 Week Range

Now: $0.08
Low: $0.07
High: $23.40

Volume

196,527 shs

Average Volume

302,299 shs

Market Capitalization

$381.27 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Motus GI?

The following sell-side analysts have issued stock ratings on Motus GI in the last year: Alliance Global Partners, and HC Wainwright.
View the latest analyst ratings for MOTS.

What is the current price target for Motus GI?

2 Wall Street analysts have set twelve-month price targets for Motus GI in the last year. Their average twelve-month price target is $28.88, suggesting a possible upside of 37,993.7%. HC Wainwright has the highest price target set, predicting MOTS will reach $37.50 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $20.25 for Motus GI in the next year.
View the latest price targets for MOTS.

What is the current consensus analyst rating for Motus GI?

Motus GI currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MOTS will outperform the market and that investors should add to their positions of Motus GI.
View the latest ratings for MOTS.

What other companies compete with Motus GI?

Other companies that are similar to Motus GI include Sintx Technologies, Bluejay Diagnostics, Better Therapeutics, Acorda Therapeutics and Ampio Pharmaceuticals. Learn More about companies similar to Motus GI.

How do I contact Motus GI's investor relations team?

Motus GI's physical mailing address is 1301 EAST BROWARD BOULEVARD 3rd Floor, FT. LAUDERDALE FL, 33301. The company's listed phone number is (954) 541-8000 and its investor relations email address is [email protected]. The official website for Motus GI is www.motusgi.com. Learn More about contacing Motus GI investor relations.